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Abstract
Background: Cognitive impairment and neuropsychiatric syndromes, like depression and apathy, are frequent
residual consequences of stroke. These have a large impact on quality of life and long-term prognosis. Several
factors are involved in the development of these residual syndromes, although their exact role and their
interrelationships remain still rather unclear. The Cognition and Affect after Stroke: a Prospective Evaluation of Risks
(CASPER) study has been primarily designed to examine whether stroke-specific (e.g. lesion location, volume, type,
severity), cerebrovascular and neurodegenerative (e.g. white matter changes, atrophy, microbleeds, perivascular spaces),
inflammatory, endothelial, and (epi)genetic markers are associated with cognitive impairment, post-stroke depression, and
post-stroke apathy, and whether they predict their course over 12 months. The secondary aims are to investigate how
the above-mentioned markers interact with each other, and to determine if patients with apathy and depression after
stroke differ in pathogenesis, course, and outcome (e.g. functional outcome, neurocognitive performance, quality of life).
Methods/design: CASPER is a 1-year prospective clinical cohort follow-up study in 250 stroke patients recruited at the
neurological in- and outpatient services at Maastricht University Medical Center (MUMC+, Maastricht, The Netherlands),
and Zuyderland Medical Center (Sittard and Heerlen, The Netherlands). At baseline (3 months post-stroke), a
neuropsychological assessment, neuropsychiatric interview, blood sample, and brain magnetic resonance imaging (MRI)
scan are conducted. Assessment of neuropsychiatric and neurocognitive status are repeated 6 and 12 months later.
Discussion: The CASPER study investigates stroke-specific, vascular, neurodegenerative, inflammatory, and genetic
markers of the development of vascular cognitive impairment, depression, and apathy after stroke. This creates the
possibility to study not only the contribution of these individual markers but also their joint contribution, which
differentiates this study from earlier stroke cohorts who lacked long-term follow-up data, a large sample size, an
extensive MRI protocol, and markers from the blood. The knowledge we derive from this study might help in
identifying markers that are associated with, or can predict the onset, maintenance, and progression of vascular
cognitive impairment, depression, and apathy after stroke, and could provide new insights into possibilities for
treatment and rehabilitation that result in better functional outcome after stroke.
Trial registration: ClinicalTrials.gov NCT02585349
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Background
Stroke is one of the leading causes of disability in the
Western world. According to the Global Burden of Dis-
ease Study in 2010 the stroke incidence worldwide was
around 17 million persons per year, with 33 million people
being still alive after stroke, with about 70 % of all stroke
patients staying with residual symptoms [1]. Stroke is the
second most frequent cause of death, after coronary artery
disease [2]. As a result of the aging population, this num-
ber will probably increase steadily in the next decades [3].
At the same time, case fatality rates are declining due to
better acute treatment. Therefore, more and more individ-
uals will need to learn how to deal with the residual dis-
abilities and handicaps [1]. Frequent impairments after
stroke are cognitive impairments and neuropsychiatric
syndromes, including depression and apathy [4, 5] which
have an impact on long-term prognosis (higher mortality
and more disability) and quality of life (QoL) of stroke sur-
vivors [6, 7].
Vascular cognitive impairment
Vascular cognitive impairment (VCI) describes the full
spectrum from mild to severe cognitive impairment in
people with cerebrovascular disease, including vascular
mild cognitive impairment and vascular (or post-stroke)
dementia (VaD) [8]. Risk factors of VCI after stroke include
event-related factors such as infarct severity, lesion volume,
age, low education, history of diabetes or atrial fibrillation,
and number of recurrent strokes [9]. The risk for post-
stroke dementia is known to be highest within the first
year, with an estimated incidence rate of 20–30%, which is
nine-times the general population’s risk [9].
It has been suggested that both vascular and neurodegen-
erative pathologies contribute to post-stroke VCI [10]. Cog-
nitive impairments can be the result of strategic infarcts,
but (pre-existing) white matter hyperintensities (WMH)
and atrophy of the medial temporal lobes can contribute
too, and they probably interact with each other, though the
nature of these interactions is not well understood [11]. In
addition, a higher risk for VCI has been reported in carriers
of the Apolipoprotein E (ApoE) ε4 allele, which is the major
genetic risk factor for Alzheimer’s disease (AD) dementia
[12]. Indeed, evidence accumulates that AD and VaD
should not be regarded as mutually exclusive diagnoses,
but rather as a continuum with pure AD and VaD at its ex-
tremes, and most people showing mixtures of both type of
pathologies [13]. While the dominating view is that vascular
changes work as a catalyst of primary neurodegenerative
changes in AD it is largely unknown whether the opposite
is true for VCI, i.e. whether AD-related changes work as a
catalyst for post-stroke dementia.
Next to neurodegeneration, neuro- and vascular in-
flammation might contribute to VCI by partly mediating
the pathophysiology underlying VCI as part of a final
common pathway [14]. Following stroke, increased auto-
immune activity is a common response, and it has been
shown that up-regulated inflammation markers like C-
reactive protein (CRP), as a consequence of a prolonged
auto-immune response, relate to poor prognosis. This in-
cludes a higher risk of additional future strokes and mortal-
ity, but also more severe VCI [15, 16]. Other enzymes,
molecules, and ligands (myeloperoxidase, soluble intercel-
lular adhesion molecule, soluble vascular cell adhesion
molecule-1, soluble E selectin, soluble P selectin and CD40
ligand) are involved in vascular inflammation as part of an
inflammatory response to stroke, and have also been found
to be increased in AD [17–20]. Also, up-regulation of pro-
inflammatory cytokines (interleukin-6 and tumor necrosis
factor alpha) and proteins (high sensitivity CRP) are risk
factors for both dementia [21, 22] and cardiovascular dis-
ease [23]. It is unknown whether similar inflammation
mechanisms are involved in cognitive deterioration in VCI,
and therefore, research is needed to investigate whether in-
flammation contributes to VCI independently or in joint
action with other (e.g. neurodegenerative) factors.
Finally, genetic factors are also suggested to play a role in
the pathogenesis of VCI, but in contrast to AD, evidence is
still scarce. A genome-wide association study in VaD iden-
tified a novel genetic locus near the androgyn receptor, and
this finding was replicated in two independent validation
datasets [24]. Polymorphisms and mutations on the genes
coding for angiotensin-converting enzyme and methylene-
tetrahydrofolate reductase are risk factors for cardiovascu-
lar diseases and might be related to the development of
VaD, although this relationship is still controversial [25].
For AD, several genetic risk loci are already identified next
to ApoE, including clusterin (CLU), phosphatidylinositol
binding clathrin assembly protein (PICALM), and encoding
complement component [3b/4b] receptor 1 (CR1) [26],
but their effects are generally small (see http://www.
alzgene.org). Whether they contribute to post-stroke
dementia is not known.
Post-stroke depression
Depression is a common neuropsychiatric syndrome fol-
lowing stroke. According to a recent systematic review by
Hackett et al. [27], around one-third of the stroke survivors
experiences depression in the first 3 months post-stroke,
and studies with long-term follow-up have shown that it is
often a chronic disorder, with a remitting-relapsing pattern
[28]. Patients with post-stroke depression (PSD) have worse
functional recovery [29], a higher risk for cognitive impair-
ment [7], and higher mortality risk [30, 31].
Early studies implied that PSD is mainly associated
with anterior lesions in the left hemisphere, however, a
major systematic review and meta-analysis found no
support for this ‘lesions location hypothesis’ [32]. Vataja
et al. [33] suggested that lesions in fronto-subcortical
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regions in general are involved in developing PSD, often
accompanied by impairments in executive functioning,
leading to what has been called the ‘depression-executive
dysfunction syndrome’. Other factors that have been as-
sociated with the development of PSD are cognitive im-
pairment, stroke severity, physicial disability, and pre-
stroke depression and anxiety [7]. Diminished QoL and
also low social support can both contribute independ-
ently to the severity of depression [34]. A study by van
Mierlo et al. [35] investigated the association between a
broad range of psychological factors and PSD with a
multivariable logistic regression analysis. They showed
that more passive coping and more helplessness, less ac-
ceptance and less perceived benefits were all significantly
and independently associated with symptoms of post-
stroke depression. Furthermore, fatigue after stroke has
been associated with PSD, although not all patients
with fatigue develop symptoms of depression and vice
versa [28].
Neuroinflammation might also play a role in the under-
lying mechanisms of PSD. Levels of CRP, soluble E selectin,
CD40 ligand, interleukin-6, tumor necrosis factor alpha, and
high sensitivity CRP are deregulated in patients diagnosed
with major depressive disorder [14, 18, 22, 23, 36–38]. In
addition, high plasma levels of neopterin are found in people
with depression, and might predict the development of PSD
[39]. Markers of endothelial function might be important as
well, since increased expression of soluble intercellular adhe-
sion molecule and soluble vascular cell adhesion molecule-1
are associated with depression [40–43]. Although several in-
flammation markers have been related to symptoms of de-
pression, studies examining these associations in PSD
specifically are relatively scarce. Some studies found an ele-
vation in interleukin-6 and tumor necrosis factor alpha in
PSD [44]. Recently, a study by Tang et al. [39] showed an as-
sociation between elevated serum levels of neopterin in the
acute phase after stroke and PSD at 6-month follow-up.
High plasma levels of homocysteine are known to in-
crease the risk for cerebrovascular disease, but have also
been associated with depressive disorders. Increased levels
of homocysteine result in cerebrovascular disease and a
deficiency in monoamine neurotransmitters, which might
lead to a depressed mood [45]. Homocysteine, folate and
vitamin B12 are all involved in methylation reactions that
are necessary for monoamine neurotransmitter produc-
tion, but also the production of phospholipids and nucleo-
tides. A deficiency in folate and vitamin B12 has also been
associated with depressive disorders [46].
Post-stroke apathy
Apathy has been defined as a disorder of diminished
motivation, characterized by lowered initiative, restricted
engagement in social interactions and activities, dimin-
ished cognitive activities, and lack of emotional response
[47]. It was traditionally seen as a symptom of other syn-
dromes (e.g. depression and dementia), but mounting evi-
dence suggests that it might be an independent syndrome
with a different etiology [48–50]. Post-stroke apathy (PSA)
is as frequent as PSD, with a mean prevalence rate of
34.6 % at 4 months post-stroke [5]. However, PSA gained
relatively less attention in research in comparison with
PSD, and most research focuses on the difference between
the two.
While PSD is suggested to be associated with left an-
terior lesions [51, 52], PSA has been associated with
right hemispheric subcortical lesions, particularly in the
basal ganglia and in the anterior cingulate circuit which
is involved in motivational processes [53–55]. Other fac-
tors associated with PSA are older age, lower education,
and severity of VCI [4, 5, 51, 56]. Furthermore, both
PSD and PSA have been associated with poor functional
recovery and low QoL [5, 29]. Overall, lack of longitu-
dinal studies, differences between time of measurement
after stroke (acute phase/chronic phase), and lack of
studies with a sufficient sample size make it difficult to
interpret study results.
In conclusion, several factors play a role in the devel-
opment of VCI, PSD, and PSA. However, most studies
investigated the underlying mechanisms in isolation and
did not take into account how several factors interact
with each other. The Cognition and Affect after Stroke,
a Prospective Evaluation of Risks (CASPER) study incor-
porates a broad range of psychosocial, blood and neuro-
imaging markers to be able to study their role alone and
in combination with each other to predict individual dif-
ferences in the onset and course of the cognitive and
neuropsychiatric consequences of stroke.
Study aims
The primary aim of CASPER is to identify stroke-related,
cerebrovascular, neurodegenerative, (epi)genetic, endothelial
and inflammation markers that are associated with VCI,
PSD, and PSA in patients with ischemic or hemorrhagic
stroke. The secondary aims are to investigate how the
above-mentioned markers interact with each other, and to
determine if patients with apathy and depression after stroke
differ in pathogenesis, course, and outcome (e.g. functional
outcome, neurocognitive performance, quality of life).
The main research questions are:
1. Are stroke-specific, additional vascular, neurodegenera-
tive, inflammatory or genetic markers a) associated with
VCI at 3 months after stroke and b) predictive for its
course over 12 months?
2. Are stroke-specific, additional vascular, neurodegener-
ative, inflammatory or genetic markers a) associated
with PSD and PSA at 3 months after stroke and b)
predictive for their course over 12 months?
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3. Do the above-mentioned markers interact on VCI,
PSD, and PSA outcome?
4. Which psychosocial factors are associated with the
development of VCI, PSD, and PSA?
5. Do PSA and PSD differ in their pathogenesis,
cognitive profile, course, and outcome?
Methods
Study design
CASPER is a prospective clinical cohort study into cog-
nitive impairments and neuropsychiatric syndromes after
stroke with a follow-up of 1 year. Baseline measure-
ments take place in the post-acute phase after stroke (i.e.
10 to 12 weeks post-stroke) to assess presence and se-
verity of VCI, PSD, and PSA. Serial assessments take
place at 6 and 12 months after baseline. The total dur-
ation of the study will be approximately 3.5 years, from
June 2013 (first in) until November 2016 (last out).
Patients
In total, 250 consecutive patients with either ischemic or
hemorrhagic stroke are included. Patients who are admitted
to the Stroke Unit of the Maastricht University Medical
Center + (MUMC+), Maastricht, the Netherlands, the
Stroke Unit of Zuyderland Medical Center in Sittard-Geleen
and Heerlen, the Netherlands, or those who visit the
Transient Ischemic Attack clinic of MUMC+ for a non-
fatal ischemic or intracerebral hemorrhagic stroke and
fulfill the in- and exclusion criteria are asked to partici-
pate. Stroke is defined as a clinical stroke syndrome
(sudden neurological dysfunction lasting >24 h, with no
apparent cause other than that of vascular origin). The
stroke can be a first-ever event or a recurrent supra- or
infratentorial stroke in a patient who recovered from a
previous event without obvious residual symptoms. Is-
chemic strokes might be cortical or lacunar, and could
be included with or without evidence of ischemia on
clinical brain scan. Hemorrhagic strokes are non-
traumatic deep, lobar, cerebellar, or brainstem hemor-
rhages as evidenced by a clinical brain scan. Eligibility
criteria are chosen to make sure that the sample will
represent the current clinical situation (Table 1). Par-
ticipation of an informant who knows the patient well
enough to answer questions about his/her functioning
over the last ± 10 years is desirable but not required.
Assessments
The baseline measurement (T0) is scheduled 3 months
post-stroke to avoid confounding effects by the acute
event, including acute inflammatory responses. At T0,
patients undergo a venipuncture, brain magnetic reson-
ance imaging (MRI) scan, neuropsychological assess-
ment and neuropsychiatric interview. They fill in several
questionnaires to assess the presence and severity of
PSD and PSA, and to evaluate other factors as functional
ability, fatigue, personality, and QoL. A semi-structured
interview with an informant is performed to provide
additional information about functional outcome of the
patient and presence of neuropsychiatric syndromes. Six
(T1) and 12 months (T2) after T0, the neuropsycho-
logical assessment and questionnaires are repeated. The
venipuncture, MRI scan, neuropsychological assessment,
and neuropsychiatric interview all take place in the aca-
demic hospital in Maastricht and are performed by spe-
cially trained nurses (venipuncture), radiology assistants
(MRI scan) and trained research (neuro)psychologists
(neuropsychological assessment and neuropsychiatric
interview). If a patient is not able to visit the hospital
due to reduced mobility, the patients are visited at their
current place of residence.
Patients who suffer from a recurrent stroke during the
12-month follow-up period will be followed-up nor-
mally, if the health status of the patient allows this, and
if the patient does not suffer from severe aphasia after
the recurrent stroke. Information about the type, loca-
tion, and severity of the lesion of the recurrent stroke is
collected, which also allows us to study the potential im-
pact of recurrent strokes on our outcome measures. Re-
current strokes are taken into account in our analyses
with longitudinal data to avoid confounding effects.
Clinical data
In a standardized case record form, data on demographics
(e.g. age, gender, educational level, ethnicity, marital status),
medical history (e.g. personal and family history of cardio-
vascular, neurological or psychiatric disorders), medication
use, physical examination (e.g. weight, height, blood pres-
sure, cholesterol), and lifestyle (smoking behavior, alcohol
consumption, drug use, physical activity) are collected.
Table 1 In- and exclusion criteria
Inclusion criteria Exclusion criteria
- Ischemic or
hemorrhagic stroke
- Subarachnoidal hemorrhage, traumatic
hemorrhage, primary intraventricular
hemorrhage and transient ischemic attack
- MMSE score≥ 15
(to ensure valid
testing)




- Severe aphasia (as it interferes with performance
on and understanding of the instructions of the
neuropsychological tests)
- Sufficient knowledge
of the Dutch language
- Evidence for pre-stroke dementia
(based on clinical diagnosis or IQ-CODE)
in the 5 years prior to the stroke
- Other existing psychiatric and neurological
diagnoses that are known to affect cognition
(Parkinson’s disease, bipolar disorder, epilepsy,
schizophrenia, or substance abuse)a
aLifetime history of depression is not considered as a reason for exclusion as it
might be a risk factor for post-stroke depression
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Neuropsychological assessment and cognitive endpoints
The neuropsychological assessment consists of a stan-
dardized battery of cognitive tests measuring specific
cognitive domains: global cognition, episodic memory,
working memory, information processing speed, execu-
tive functioning, visuoconstruction, neglect, premorbid
IQ, and language (dysphasia). An overview of all test in-
struments and their cognitive domains is presented in
Table 2. The neuropsychological tests are administered
according to a standardized test protocol by trained re-
search (neuro)psychologists.
VCI is defined as a score ≤ 1.5 standard deviations
below the general population mean in one or more cog-
nitive domains, based on available norm scores for age,
gender, and level of education for the Dutch general
population. In addition, there should not be any interfer-
ence in daily activities and no diagnosis of dementia ac-
cording to DSM-V criteria [57]. The impairments have
to represent a significant decline from premorbid levels
of functioning. The diagnosis and type of dementia is
made by an experienced neuropsychiatrist or neuro-
psychologist based on DSM-V criteria [57]. A consensus
meeting is arranged when there is a discrepancy in diag-
nosis, and if no consensus can be reached, the patient
will be considered not demented. The diagnosis of AD is
made according to the standardized clinical criteria for
AD based on the National Institute for Neurological and
Communicative Disorders and Stroke-Alzheimers Dis-
ease and Related Disorders Association (NINCDS-
ADRDA) criteria [58]. The diagnosis of VaD is made ac-
cording to the criteria proposed by the National Institute
of Neurological Disorders and Strokes – Association
Internationale pour la Recherche et l’Enseignement en
Neurosciences (NINDS-AIREN) [59].
The Informant Questionnaire on Cognitive Decline in
the Elderly (IQ-CODE; short form) is used to detect pos-
sible dementia prior to the index stroke, and is rated
retrospectively (past 5 years prior to the index stroke)
[60], in combination with information from medical re-
cords. A cut-off score ≥ 3.60 is used to indicate possible
dementia prior to the stroke, as has been used in a pre-
vious study with stroke patients [61].
Neuropsychiatric assessment
Depression
The symptoms of a major depressive disorder according
to DSM-IV and V are assessed with the Mini Inter-
national Neuropsychiatric Interview (M.I.N.I.) [62]. The
MINI is a semi-structured interview administered to the
patient and consists of three different parts, which aim
to determine whether the patient can be diagnosed with
a current major depressive disorder, a depressive episode
lifetime, and a current dysthymic disorder. The
clinician-rated Montgomery-Åsberg Depression Rating
Scale (MADRS) is used to assess the severity of symp-
toms of depression [63]. This rating scale consists of 10
items to evaluate the severity of depressive symptoms
and is filled out by the clinician [63]. In addition, the
Hospital Anxiety and Depression Scale (HADS), a 14-
item self-report scale, is used to identify clinically signifi-
cant levels of anxiety and depression [64]. According to
a study by Kang et al. [65], the HADS and MADRS are
especially valid as screening instrument for PSD (in both
the acute and chronic phase), since these scales focus
less on the presence of somatic symptoms, resulting in
less misclassification.
Apathy
The Apathy Evaluation Scale (AES) is an 18-item scale
used to evaluate the presence and severity of apathy
[66]. Three different versions of the AES are available, a
clinician-rated (administered to the patient), informant-
rated, and a patient-rated version. The AES has been
rated as the most favorable instrument for assessing
Table 2 Neuropsychological measures and neuropsychiatric
questionnaires
Instrument T0a T1a T2a
Global cognition MMSE [89] X X X
Episodic Memory 15-Word Verbal Learning Test [90] X X X
Working memory Digit-span of the WAIS-III [91] X X X
Information
processing speed
Digit Symbol Substitution Test (DSST)
Trail Making Test (TMT; part A




TMT (interference), BADS Zoo Map &
Key Search, Verbal Fluency (60 s;
animals and professions) [92–94]
X X X
Visuo-construction Clock drawing [94] X X X
Neglect Star cancellation [95] X
Premorbid IQ NLV [96] X
Language/aphasia Boston Naming Test [97] X
Depression MINI, MADRS, HADS, NPI [62–64, 68] X X X
Apathy AES, NPI [66, 68] X X X
Premorbid
dementia
IQ CODE [60] X
Functional ability Barthel Index, Lawton [73, 74] X X X
Quality of life SS-QoL [75] X X X
Fatigue15 FSS [72] X X X
Personality16 NEO-FFI [76] X
aT0: baseline measurement, T1: 6-month follow-up, T2: 12-month follow-up
Abbreviations: MMSE Mini Mental State Examination, WAIS Wechsler Adult
Intelligence Scale, BADS Behavioral Assessment of the Dysexecutive Syndrome,
NLV Nederlandse leestest voor volwassenen (Dutch version of the National
Adult Reading Test), MINI Mini International Neuropsychiatric Interview, MADRS
Montgomery-Åsberg Depression Rating Scale, HADS Hospital Anxiety and
Depression Scale, NPI Neuropsychiatric Inventory, AES Apathy Evaluation Scale,
IQ-CODE Informant-Questionnaire on Cognitive Decline in the Elderly, SS-Qol
Stroke Specific Quality of Life, FSS Fatigue Severity Scale, NEO-FFI NEO Five
Factory Inventory
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apathy, with the clinician-rated version being most valid
of the three different versions [67]. Both the informant-
rated and clinician-rated version (administered to the
patient) of the AES are used in the CASPER study.
Generic
The Neuropsychiatric Inventory (NPI) is administered as
a semi-structured interview to the informant of the pa-
tient [68]. The NPI is originally developed to evaluate
neuropsychiatric symptoms in dementia, but is also fre-
quently used in the stroke population [28]. It evaluates the
presence and severity of 12 different neuropsychiatric
symptoms (delusions, hallucinations, agitation, depression,
anxiety, euphoria, apathy, disinhibition, irritability, aber-
rant motor behavior, sleep, and appetite) [69]. The validity
and reliability of the NPI, including the Dutch version, has
been well established [70, 71].
Additional interviews
Fatigue after stroke is assessed with the Fatigue Severity
Scale (FSS) [72]. This 9-item self-rating scale can be an-
swered on a 7-point scale, with higher scores representing
more fatigue. The Barthel Index [73] is used to evaluate
impairments in activities of daily living (ADL), and the
Lawton Scale [74] is used to assess impairment in instru-
mental ADL. Furthermore, the Stroke Specific Quality of
Life Scale (SS-QoL) is used to evaluate health-related
QoL, which is defined as the physical, psychological, and
social aspects of life that can be influenced by a change in
health status [75]. The NEO Five Factor Inventory (NEO-
FFI) is used to assess the big-five dimensions of personal-
ity, which are extraversion, neuroticism, openness to new
experiences, agreeableness, and conscientiousness [76].
Neuroimaging
A standardized brain MRI protocol is used as described in
Table 3. The MRI scans are all performed on the same 3.0
Tesla head-only scanner equipped with an 8-channel head
coil (Philips Achieva, Philips Medical Systems, Best, The
Netherlands), using the same standardized scanning proto-
col for every patient. This protocol has been optimized for
stroke and WMH segmentation, as well as segmentation
of the hippocampus [77]. One scanning session takes
approximately 30 min. After acquisition of the MR images,
an anonymisation procedure is performed, to make sure
that all imaging data are pseudonymised.
MRI markers
Several stroke characteristics are visually scored by an expe-
rienced vascular neurologist and consist of: presence and
type of symptomatic stroke lesion (ischemic/hemorrhage),
location of the lesion, number, type, and location of old in-
farcts and old hemorrhages, number and location of micro-
bleeds, and degree of perivascular spaces in basal ganglia
and centrum semiovale. The Fazekas visual rating scale is
used to score deep and periventricular WMH [78]. In
addition, a semi-automatic brain tissue segmentation pro-
gram, based on the program used in the Rotterdam scan
study [79], is used to measure WMH volumes and to calcu-
late the volume of global brain atrophy, corrected for total
intracranial volume. The accuracy of this semi-automated
method appeared to be within the range of the inter-
observer variability of fully manual segmentations but is
less time-consuming while still requiring some manual cor-
recting. The medial temporal lobe atrophy (MTA) visual
rating scale [80] is used to indicate the level of atrophy in
the medial temporal lobes (ranging from 0 to 3), separately
for the left and the right hemisphere. Furthermore, hippo-
campal volume is measured based on atlas registration with
high accuracy using the robust and validated method of
learning embeddings for atlas propagation (LEAP) [81, 82].
Blood markers
At baseline, fasting blood samples are taken. All patients
take their morning medication after the venipuncture. In
total, 35.5 mL of blood are taken and directly analyzed or
stored. We measure several inflammation markers. In
addition, standard lab procedures to assess levels of glu-
cose, cholesterol (total, high-density lipoprotein cholesterol,
low-density lipoprotein cholesterol), and triglycerides will
be performed directly after the venipuncture [83–85]. Bio-
material (including deoxyribonucleic acid and ribonucleic
acid) is stored anonymously for 15 years after the end of
the study. Table 4 lists the blood markers investigated in
CASPER.
Table 3 Brain MRI protocol










Coronal 3D T1-weighted (TFE) 240 × 240 240 × 240 160 0 1 1 × 1 × 1 8.2/3.8
2D Axial T2-weigthed (FSE) 230 × 185 328 × 225 48 0 3 0.7 × 0.8 × 3 3000/80
3D fluid-attenuation inversion recovery 250 × 250 228 × 226 283 0 1.1 0.6 × 1.1 × 1.1 8000/332/2400
T2* diffusion weighted imaging Gradient echo EPI 240 × 240 128 × 128 28 0 5 1.85 × 1.85 × 5 10000/72/2400
SWI 220 × 180 220 × 180 260 0 0.5 1 × 1 × 0.5 16/22
Abbreviations: TR repetition time, TE echo time, TI inversion time, TFE turbo field echo, FSE fast spin echo, EPI echo planar imaging, SWI susceptibility weighted imaging
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Ethics, consent, and permissions
The study protocol has been approved by the Medical
Ethics Committee of MUMC+. The research is per-
formed according to the principles of the Declaration of
Helsinki 59th WMA General Assembly, Seoul, (October
2008) and in accordance with the Dutch Medical Re-
search Involving Human Subjects Act (WMO). All eli-
gible patients are informed about the aim of the study
and both the patient and informant receive an informa-
tion letter. All patients receive enough time to consider
participation and if they agree to participate, an appoint-
ment is scheduled to sign informed consent. There are
no risks for the patients participating in this study. All
assessments in the study consist of routine operations
and all patient data are pseudonymised. Contraindica-
tions for MRI are checked for every patient, and patients
with contraindications are excluded for MRI. If a patient
decides to withdraw from the study, this has no conse-
quences or risks for the patients. Patients who refuse
follow-up assessment are contacted to determine the
reason for refusal.
Power calculation and sample size
Based on results of the CODAS study [86], a previous
study with stroke patients of our research group, it is ex-
pected that 50 % of the stroke patients will have VCI and
10 % will have VaD after 1 year. Furthermore, it is ex-
pected that 35 % of the patients will have minor or major
depression after 1 year post-stroke [87]. A power calcula-
tion was performed with the freeware program G*Power
version 3.1 (http://www.gpower.hhu.de) assuming categor-
ical independent variables to which 50 % are exposed and
50 % are not exposed (median-split), since no reliable esti-
mates are available for our main predictors from literature
(MRI, inflammation, and genetics). Based on a 1-year
follow-up, a two-sided alpha level of .05, and an expected
drop-out rate of 20 % based on the CODAS study (about
10 % due to death), a sample size of 250 resulted in a
power of 86 % to detect a relative risk of 2.00, or 80 % to
detect a relative risk of 1.89 for PSD, and a 96 % power to
detect a relative risk of 2.00, or 80 % power to detect a
relative risk of 1.70 for VCI.
Statistical analyses
Categorical data will be presented on group level
expressed in absolute numbers and percentages, whereas
continuous data will be presented by their mean, confi-
dence interval, and standard deviation. In case of non-
normality, continuous data will be presented as medians
with their corresponding inter-quartile range. Differences
between groups will be analyzed using t-tests for continu-
ous variables or appropriate non-parametric counterparts,
and chi-square tests for categorical variables. Pearson’s
correlation coefficient will be used to assess the associ-
ation between two continuous variables. Random effects
models will be used to measure cognitive decline from
baseline to follow-up, which has the advantage over re-
peated measures ANOVA that it is not restricted to study
completers. The effect of baseline predictors on PSD,
PSA, and VCI will be estimated with Poisson and Cox re-
gression, taking into account differences in individual
follow-up time. Furthermore, multivariate finite mixture
modeling will be used to test the existence of separate
PSD and PSA subtypes, using lesion location, WMH, in-
flammation markers, genetic risk factors, functional im-
pairment, and cognitive functioning as subtype indicators.
Age, gender, and education will be included as covariates
in the multivariate models. Based on theory and statistical
Table 4 Blood sampling procedure
Tubes Blood markers Procedure
EDTA tube (4 × 6.0 mL) Myeloperoxidase, neopterin, soluble intercellular
adhesion molecule, soluble vascular cell adhesion
molecule-1, soluble E selectin, soluble P selectin,
CD40 ligand, interleukin-6, tumor necrosis
factor alpha, Homocysteine
Transported on ice to the Biobank Maastricht
UMC+ where the blood is preprocessed
before storing. EDTA plasma is centrifuged
and stored at −80 °C until analysis.
Natriumfluoride/EDTA tube (1x 4.0 mL)
Coagulation tube (1 × 5.0 mL)
Glucose, total cholesterol high-density lipoprotein-
cholesterol, low-density lipoprotein-cholesterol,
triglyceride, folate, vitamine B12, high sensitivity
C-reactive protein
Direct analyses of these markers are performed
at the laboratory on the day of sample collection
after centrifuging.
Buffycoats from the 4 EDTA tubes for
DNA extraction
Apoliprotein E, clusterin, phosphatidylinositol binding
clathrin assembly protein, encoding complement
[3b/4b] receptor 1, angiotensin-converting enzyme,
methylenetetrahydrofolate reductase
Buffycoats are taken from four EDTA tubes and
separately stored at the Biobank until analysis.
Epigenetics 1 PAXgene tube (2.5 mL) RNA Blood is collected in PAXgene tubes to ensure
long-term stability of ribonucleic acid and the
tubes are stored at the Biobank. RNA extraction
and subsequent analysis of expression of
inflammatory and stroke-related genes at the
mRNA level will be done.
Abbreviations: mL milliliter, EDTA ethylenediaminetetraacetic acid, DNA deoxyribonucleic acid, RNA ribonucleic acid, mRNA messenger ribonucleic acid
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evaluation to see whether a variable might be a probable
confounder it will be decided which additional covariates
will be added on each analysis.
Discussion
The CASPER study is a prospective clinical cohort study
examining predictors of onset and course of VCI, PSD,
and PSA using a deep phenotyping approach. It is an ob-
servational study with minimal risks for the participating
patients. The longitudinal design creates the possibility
to study independent predictors of VCI, PSD, and PSA.
The CASPER study provides the possibility to study the
course of these conditions and potential bidirectional rela-
tionships between them. A relatively large sample size and
a MRI protocol that uses state-of-the-art volumetry of
WMH and hippocampal atrophy make it more likely to
find subtle differences in the brain’s macrostructure.
Therefore, the CASPER study has an additional value to
earlier stroke cohort studies (e.g. Sydney Stroke Study,
The Fogarty-Mexico Stroke Cohort, CODAS) [10, 86, 88].
Furthermore, CASPER includes extensive blood-based
biomarker data which results in a rich phenotyping ap-
proach generating both blood-based biomarker data and
clinical brain MRI data, creating the possibility to study
cerebrovascular, neurodegenerative, inflammatory, and
genetic markers, and their inter-relationships. This is valu-
able since this gives a better account of how these changes
occur in patients, namely in combination. Hence, the
combination of these markers may predict individual dif-
ferences in the development of VCI, PSD, and PSA better
than each marker in isolation. Taken together, these meth-
odological strengths promise to yield novel insights into
the underlying mechanisms of the burdensome conse-
quences of stroke.
However, some limitations of the study protocol have
to be acknowledged here. Although the extensive in-
and exclusion criteria were formulated with caution,
they can possibly result in a less representative group of
patients compared to the general stroke population. For
instance, patients who are aphasic or who have pre-
existent cognitive disturbances are excluded. No data are
collected in the acute phase after stroke, which could
yield additional information on the association between
VCI, PSD, PSA and the earlier mentioned investigated
markers, but a post-acute baseline time point is chosen
to avoid confounding effects in the acute phase (e.g. gen-
eric acute inflammatory response, sickness behavior).
MRI scans and venipuncture are only performed on T0,
since it is not feasible due to logistical and financial rea-
sons to repeat them at T1 and T2. However, if these data
could also have been collected more information on the
causes of VCI, PSD, and PSA could have been gathered,
e.g. by linking longitudinal changes on MRI to changes
in outcomes. Furthermore, patients with severe stroke
are less probable to participate in the study, as the assess-
ment is quite extensive. This can result in a cohort of pa-
tients with relatively mild stroke, which may influence the
frequency of VCI, PSD, and PSA. Both ischemic and
hemorrhagic strokes are included to increase the inclusion
rate, however, due to the different etiologies of these
strokes, it is likely that this limits the generalizability of
the results. Therefore, we have to correct for stroke type
in our analyses to take this into account. It is also likely
that patients with depression or apathy after stroke are
less motivated to participate in the study, resulting in an
underestimation of the PSD and PSA prevalence in the
study sample. In addition, the current follow-up period of
1 year allows testing predictions in the post-acute to early
chronic phase, but is too short to study long-term conse-
quences. Finally, CASPER allows for in-depth phenotyping
and also covers a broad spectrum of factors impacting on
the consequences of stroke, but it is not powered to test
for more subtle associations or to use complex genetic
models or testing of rare variants. Therefore, the study is
also designed as to allow harmonization with other stroke
cohorts in larger meta-studies as part of the STROKOG
consortium (https://cheba.unsw.edu.au/group/strokog).
In conclusion, the CASPER study allows to study the
role of several markers, consisting of cerebrovascular, neu-
rodegenerative, and inflammatory markers, and their
inter-relationships, in the development of VCI, PSD, and
PSA. Furthermore, the longitudinal design and sample size
provide the possibility to study the course of PSA, PSD,
and VCI and to explore individual differences in their de-
velopment. Better understanding of the role of all of these
markers will make it possible to provide new treatment
techniques or adapt existing treatment techniques, both
on a biological and psychological level, which can result in
better QoL and functional outcome of stroke patients.
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